PAR-21-183: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
August 8, 2021 - January 10, 2024
Address
Chicago, IL 60612
Calendar
Download iCal FileRelated Announcements
PAR-21-183 - Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
Issued by
National Institute on Drug Abuse (NIDA)
Purpose
This Notice informs applicants of a changes to the Key Dates for Funding Opportunity Announcement (FOA) PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)".
The following Section of PAR-21-183 has been modified to reflect the changed dates:
Currently Reads:
Part 1. Overview Information
Key Dates
Open Date (Earliest Submission Date):
August 8, 2021
Letter of Intent Due Date(s):
30 days prior to application due date
Application Due Dates
Review and Award Cycles
New
Renewal / Resubmission / Revision (as allowed)
AIDS
Scientific Merit Review
Advisory Council Review
Earliest Start Date
September 08, 2021
September 08, 2021
September 08, 2021
November 2021
January 2022
April 2022
January 10, 2022
January 10, 2022
January 17, 2022
March 2022
May 2022
July 2022
September 08, 2022
September 08, 2022
September 08, 2022
November 2022
January 2023
April 2023
January 10, 2023
January 10, 2023
January 10, 2023
March 2023
May 2023
July 2023
September 08, 2023
September 08, 2023
September 08, 2023
November 2023
January 2024
April 2024
January 10, 2024
January 10, 2024
January 10, 2024
March 2024
May 2024
July 2024
Expiration Date:
January 11, 2024
Modified to Read (changes shown in bold italics):
For more information click here
Date posted
Apr 7, 2021
Date updated
Apr 7, 2021